Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence

ABSTRACT Introduction Extensive small cell lung cancer (ES‐SCLC) are currently managed using first‐line chemotherapy options, including atezolizumab (Atezo) plus etoposide and carboplatin (CE) or durvalumab (Durva) plus etoposide with either cisplatin (PE) or carboplatin (CE). However, a definitive...

詳細記述

書誌詳細

主要な著者:	Yuta Yamanaka, Yukiko Okuno, Keisuke Kamisako, Yuta Okazaki, Kentaro Nakanishi, Yume Sanada, Kiyori Yoshida, Tatsuki Ikoma, Yuki Takeyasu, Utae Katsushima, Hiroshige Yoshioka, Takayasu Kurata
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2024-12-01
シリーズ:	Cancer Medicine
主題:	atezolizumab durvalumab extensive‐stage small cell lung cancer first‐line treatment immune checkpoint blockade real‐world evidence
オンライン･アクセス:	https://doi.org/10.1002/cam4.70480
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!